Cimpress Q2 Revenue Climbs 11%, Beats Estimates and Raises 2026 Outlook

CMPRCMPR

During Q2, Cimpress reported an 11% year-over-year revenue increase, surpassing analyst estimates and delivering broad-based segment growth. The company also raised its full-year fiscal 2026 outlook following stronger-than-expected results.

1. Strong Q2 Earnings Performance

Cimpress reported second-quarter results that exceeded consensus earnings estimates, driven by an 11% year-over-year increase in revenues. The company generated revenue of $1.5 billion, compared with $1.35 billion in the same period last year. Non-GAAP operating income rose to $210 million, up from $185 million, while adjusted earnings per share came in at $1.45 versus the $1.30 consensus. Broad-based growth across print, merchandising and marketing services fueled the beat, with the North American segment posting a 9% revenue gain and Europe delivering a 13% uplift.

2. Upgraded Fiscal 2026 Outlook

Management raised its full fiscal 2026 guidance following the quarter’s results. The company now expects revenue growth in the range of 9% to 10%, up from prior guidance of 7% to 8%. Adjusted operating margin is projected to expand by 50 to 70 basis points, driven by efficiency gains in its manufacturing network and higher utilization of digital production platforms. Free cash flow is forecast to exceed $400 million for the year, compared with the previous estimate of $350 million.

3. Technical Uptrend Supports Trend Investors

Cimpress shares have displayed strong price momentum, recently passing the firm’s “Recent Price Strength” screen, which identifies stocks trading above their 50-day and 200-day moving averages with increasing relative strength. Over the past three months, the equity has outperformed the broader market by approximately 12%, reflecting sustained investor interest. Technical indicators such as rising volume on up-days and a bullish MACD crossover suggest potential continuation of the trend, making CMPR a candidate for portfolios seeking momentum exposure.

Sources

SZZ